Loading…
Gain Therapeutics, Inc. is projected to rise to $1.88 by 2027, a +6% move from its current price of $1.77. GANX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.71 | $1.77 | $1.83 | -0.05% |
| May 30 | $1.68 | $1.77 | $1.86 | -0.11% |
| May 31 | $1.66 | $1.77 | $1.88 | -0.16% |
| Jun 1 | $1.65 | $1.77 | $1.89 | -0.21% |
| Jun 2 | $1.63 | $1.77 | $1.91 | -0.27% |
| Jun 3 | $1.62 | $1.76 | $1.92 | -0.32% |
| Jun 4 | $1.61 | $1.76 | $1.93 | -0.38% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.61 | $1.76 | $1.93 | -0.38% |
| Week 2 | $1.54 | $1.76 | $2.00 | -0.75% |
| Week 3 | $1.49 | $1.75 | $2.05 | -1.12% |
| Week 4 | $1.45 | $1.74 | $2.09 | -1.49% |
| Week 5 | $1.42 | $1.74 | $2.13 | -1.86% |
| Week 6 | $1.38 | $1.73 | $2.16 | -2.23% |
| Week 7 | $1.35 | $1.72 | $2.19 | -2.60% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Gain Therapeutics, Inc. is a biotechnology company that develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its Magellan platform discovers novel allosteric binding sites in a disease and identifies proprietary small molecules that bind these sites to modulate protein function, addressing the underlying cause of disease.
Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. Gain Therapeutics has various small molecule drug candidates in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc.
was founded in 2017 and is based in Bethesda, Maryland.
GANX is a biotechnology stock with a current price of $1.78 and a market cap of $75.92M. It is ranked 4397 by market capitalization. The near-term technical setup shows bearish sentiment, with the stock trading near key supports and resistances.
A major floor 27.5% below — a decisive break under it would weaken the trend.
The nearest floor, 10.2% below — buyers have tended to step in here.
The nearest ceiling, 20.9% above — a clean break opens room to run.
A major ceiling 72.3% above — clearing it would confirm fresh momentum.
Key GANX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GANX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.75 | Buy | $1.76 | Buy |
| MA 10 | $1.73 | Buy | $1.76 | Buy |
| MA 20 | $1.79 | Sell | $1.80 | Sell |
| MA 50 | $1.89 | Sell | $1.92 | Sell |
| MA 100 | $2.06 | Sell | $2.05 | Sell |
| MA 200 | $2.19 | Sell | $2.12 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.24 | Neutral |
| Stoch RSI (14) | 81.72 | Sell |
| CCI (20) | -21.98 | Neutral |
| Williams %R (14) | -35.71 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -2.75 | Sell |
| Bollinger %B (20,2) | 0.44 | Neutral |
| Stochastic %K (14) | 64.29 | Neutral |
| TRIX (15) | -0.50 | Sell |
| Awesome (5,34) | -0.11 | Sell |
| Ultimate (7,14,28) | 47.04 | Neutral |
| Momentum (10) | -0.03 | Sell |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 1.81 | Sell |
| ADX (14) | 14.12 | Neutral |
| ATR (14) | 0.06 | Info |
The 30-day technical picture is bearish with RSI (14) at 50. The price is trading below both the 50-day and 200-day moving averages, with the SMA50 at $1.91 and the SMA200 at $2.19. Immediate support is at $1.59 and resistance at $2.14. Over the last 30 days, the price range has been from $1.40 to $2.26.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.59 | $1.77 | $2.26 | 0% | Neutral | |
| $1.46 | $1.88 | $2.60 | +6% | Neutral | |
| $1.37 | $1.83 | $2.64 | +3% | Neutral | |
| $1.63 | $2.25 | $3.36 | +27% | Bullish | |
| $2.04 | $2.90 | $4.45 | +64% | Bullish | |
| $2.21 | $3.21 | $5.05 | +81% | Bullish | |
| $2.38 | $3.54 | $5.70 | +100% | Bullish | |
| $2.19 | $3.33 | $5.48 | +88% | Bullish | |
| $2.25 | $3.50 | $5.86 | +98% | Bullish | |
| $2.68 | $4.24 | $7.23 | +140% | Bullish | |
| $3.41 | $5.91 | $10.83 | +234% | Bullish | |
| $6.72 | $13.75 | $27.94 | +677% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.59 | $1.77 | $2.08 | +0.00% |
| June 2026 | $1.45 | $1.71 | $2.07 | -3.48% |
| July 2026 | $1.41 | $1.69 | $2.08 | -1.35% |
| August 2026 | $1.43 | $1.72 | $2.15 | +2.26% |
| September 2026 | $1.40 | $1.69 | $2.14 | -1.69% |
| October 2026 | $1.34 | $1.64 | $2.09 | -3.17% |
| November 2026 | $1.37 | $1.69 | $2.17 | +2.81% |
| December 2026 | $1.41 | $1.74 | $2.26 | +3.37% |
Click any year to see its month-by-month GANX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The GANX price prediction for 2026 points to an average of $1.77 (low $1.59, high $2.26) — a potential gain of 0% on today's $1.77. A consolidation phase looks the most probable path here.
In 2027, GANX is projected to trade between $1.46 and $2.60, averaging $1.88 — a potential gain of +6% from today's $1.77. That is up +6% on the projected 2026 average. Price action looks broadly range-bound.
Gain Therapeutics, Inc.'s 2028 outlook centres on $1.83, within a $1.37 to $2.64 range. That is -3% versus the projected 2027 average. That marks a +3% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, GANX could reach as high as $3.36, with a base case around $2.25 and support toward $1.63 — roughly +27% from $1.77. Momentum favours further upside here.
Expect GANX to range from $2.04 to $4.45 through 2030. The $2.90 average target implies a +64% move from current prices. That is up +29% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The GANX price prediction for 2031 points to an average of $3.21 (low $2.21, high $5.05) — a potential gain of +81% on today's $1.77. Momentum favours further upside here.
In 2032, GANX is projected to trade between $2.38 and $5.70, averaging $3.54 — a potential gain of +100% from today's $1.77. That is up +10% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Gain Therapeutics, Inc.'s 2033 outlook centres on $3.33, within a $2.19 to $5.48 range. That is -6% versus the projected 2032 average. That marks a +88% change versus current levels. Momentum favours further upside here.
By 2034, GANX could reach as high as $5.86, with a base case around $3.50 and support toward $2.25 — roughly +98% from $1.77. Buyers look set to stay in control over this stretch.
Expect GANX to range from $2.68 to $7.23 through 2035. The $4.24 average target implies a +140% move from current prices. That is up +21% on the projected 2034 average. Momentum favours further upside here.
The GANX price prediction for 2040 points to an average of $5.91 (low $3.41, high $10.83) — a potential gain of +234% on today's $1.77. Buyers look set to stay in control over this stretch.
In 2050, GANX is projected to trade between $6.72 and $27.94, averaging $13.75 — a potential gain of +677% from today's $1.77. That is up +133% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in GANX today (≈ 564.971751 GANX) could be worth
$7,769.17
+$6,769.17 (+677%) by 2050 · US Dollar
Based on the average projected GANX price of $13.75 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GANXwould be worth at today's price.
$1,000 invested in GANX on May 27, 2025 (≈ 564.971758 GANX) would be worth
$1,000
+$0 (+0.0%) today · 1.00× · US Dollar
Based on a GANX entry price of $1.77 vs. today's $1.77.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.65 | $1,072.73 | +7.3% |
| 1 month ago | $1.95 | $907.69 | -9.2% |
| 3 months ago | $2.48 | $713.71 | -28.6% |
| 6 months ago | $3.5 | $505.71 | -49.4% |
| 1 year ago | $1.77 | $1,000 | +0.0% |
| All time (5.0y) ago | $10.79 | $164.04 | -83.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GANX forecast.
Our base-case forecast reaches $3.50 around 2032.
Implied market cap at $3.50: $149.29M
The multi-year forecast shows meaningful upside beginning from 2030 and beyond. In 2030, the Avg price is projected to be $2.59 with a ROI of 45.6% and a Bullish sentiment. Earlier years carry more modest moves: 2026 Avg $1.78, ROI 0%; 2031 Avg $2.88, ROI 61.7%; 2032 Avg $3.11, ROI 74.8%; 2035 Avg $3.54, ROI 99.1%.
By 2040, the Avg rises to $4.85 with a ROI of 172.3% and a Bullish sentiment, and by 2050 the Avg is $10.88 with a ROI of 511% and a Bullish sentiment. These projections illustrate substantial longer-term upside but remain estimates, not guarantees, and the path includes year-to-year variability.
Tap a question to reveal the answer.
2030 Avg: $2.59; Min: $1.81; Max: $4.02; ROI: 45.6%; Sentiment: BULLISH.
The forecast shows a neutral to bullish progression after 2026, with 2026 Avg $1.78 (ROI 0%), 2027 Avg $1.80 (ROI 1.4%), 2028 Avg $1.72 (ROI -3.2%), 2029 Avg $2.03 (ROI 14.2%), and then stronger upside from 2030 onward (2030 Avg $2.59, ROI 45.6%). These are estimates and not guarantees.
Yes, the forecast projects an Avg price of $10.88 in 2050 with a ROI of 511%, and a max forecast of $22.49 in 2050, indicating potential for around or above $10 in the long run, though this is not guaranteed.
Current price: $1.78. Market cap: $75.92M.
The forecast implies notable volatility with year-to-year changes and a high long-term ROl potential. The 30-day range is $1.40 to $2.26, and the annualized volatility is 70%.
Gain Therapeutics, Inc. Community Discussion
0Share your Gain Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.